36results about "CD44" patented technology

Pharmaceutical compositions and methods for treating cancer using CD44 antagonists are disclosed. In certain aspects, these pharmaceutical compositions and methods include treating a mammal having a cancer, such as glioma, colon cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, renal cell carcinoma, gastric cancer, esophageal cancer, head cancer, neck cancer, pancreatic cancer, or melanoma, with a CD44 fusion protein. These CD44 fusion proteins include CD44-Fc fusions and can be used to detect hyaluronan.

The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of cancer and angiogenesis related diseases using cyclic peptides.

The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

The present invention relates to a protein which binds to the domain encoded by exon 9 of human CD44 (CD44ex9), to fusion proteins and conjugates of said protein and especially to nanoparticles conjugated to said protein. The invention further relates to a method of production for the protein and the respective conjugated nanoparticles and the use of the protein of the invention for treatment and diagnosis of cancer diseases.

The invention relates to a fusion protein comprising a polypeptide of interest, a transmembrane domain and an HIV gag polypeptide, or their functionally equivalent variants. The invention also relates to the polynucleotides, vectors, host cells and virus-like particles expressing or presenting said fusion proteins and to the pharmaceutical, immunogenic or vaccines composition containing said fusion proteins, polynucleotides, vectors, host cells and virus-like particles and their use in human and veterinary medicine.

The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for use in the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.

The invention provides epitope polypeptide CD44-P2 based on a prostatic cancer stem cell marker CD44 and an application of the epitope polypeptide CD44-P2 and relates to the technical field of biological medicine engineering. According to the epitope polypeptide CD44-P2 based on the prostatic cancer stem cell marker CD44 and the application of the epitope polypeptide CD44-P2, the epitope polypeptide based on the prostatic cancer stem cell surface marker CD44 is designed and synthesized by a bioinformatics means, can sacrificially activate cytotoxic T lymphocytes, has good killing effects, canbe used for developing therapeutic peptide vaccines targeting prostatic cancer stem cells, a new technical scheme is provided for precise immunotherapy of malignant prostatic cancer, prostatic cancerstem cells can be specifically targeted, and relapse of prostatic cancer is reduced fundamentally.

Methods and compositions are provided for the treatment and diagnosis of diseases related to hyperglycemic conditions, including diabetes, insulin resistance, and the like. Genetic polymorphisms are shown to be associated with disease susceptibility, and their detection is used in the diagnosis of a predisposition to these conditions. The corresponding proteins are useful as targets for therapeutic intervention.

The present invention relates to a bFGF mesenchymal stem cell exosome and its preparation method and application. The bFGF mesenchymal stem cell exosome is secreted by mesenchymal stem cells and can express bFGF fusion protein on the mesenchymal stem cell membrane of exosomes. In the present invention, for the first time, bFGF is expressed on the membrane of mesenchymal stem cells and mesenchymal stem cell exosomes in the form of fusion protein, which can express a large amount of bFGF protein, and can enhance the specific targeting of mesenchymal stem cell exosomes , Significantly improves the effect of wound repair and reduces the formation of scars. The present invention provides a new safe and efficient drug or medical preparation or medical aesthetic product for promoting tissue repair.

The invention discloses a cow mammary gland epithelial cell line knocked out of the CD44 gene and a construction method thereof. The method utilizes a recognition sequence of a gRNA knocking out the CD44 gene, the nucleotide sequence of which is shown in SEQ ID NO:1. The present invention utilizes the gRNA designed by the inventor to accurately and efficiently knock out the CD44 gene, and effectively constructs a dairy cow mammary epithelial cell with the CD44 gene knocked out. The present invention solves the defect of low interference efficiency in RNAi technology and provides a A simple and efficient method for constructing gene knockout cell lines. CD44 gene is an important marker gene related to lipid metabolism and fatty acid metabolism. The establishment of its knockout cell line also provides effective genetic materials and genetic tools for further research on the functions of genes related to lipid metabolism and fatty acid metabolism pathways.

The present invention concerns a novel CD44-like protein receptor. In particular, isolated nucleic acid molecules are provided encoding the CD44-like protein. CD44-like polypeptides are also provided, as are screening methods for identifying agonists and antagonists capable of enhancing or inhibiting CD44-like protein-mediated signaling. The invention further concerns therapeutic methods for treating diseases associated with processes mediated by CD44-like protein signaling.

Provided are methods and compositions for cartilage repair. The method involves performing a surgical procedure at the site of a cartilage defect and administering a composition comprising a receptor for hyaluronan mediated motility (RHAMM)-mimetic peptide, and a high molecular weight hyaluronan.

Provided are alternative splicing constructs and methods for their use. In particular, CD44 based alternative splicing constructs are provided that include CD44 exon 5. These alternative splicing constructs are useful in high-throughput assays for testing the effects of compounds on splicing and for achieving targeted cell death.